Found: 33
Select item for more details and to access through your institution.
Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3791, doi. 10.1111/dom.15724
- By:
- Publication type:
- Article
iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2005, doi. 10.1111/dom.15074
- By:
- Publication type:
- Article
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2391, doi. 10.1111/dom.14825
- By:
- Publication type:
- Article
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 11, p. 2182, doi. 10.1111/dom.14803
- By:
- Publication type:
- Article
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1522, doi. 10.1111/dom.14722
- By:
- Publication type:
- Article
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan‐O randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 34, doi. 10.1111/dom.14543
- By:
- Publication type:
- Article
Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1331, doi. 10.1111/dom.14345
- By:
- Publication type:
- Article
Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1567, doi. 10.1111/dom.14068
- By:
- Publication type:
- Article
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide ( iGlarLixi) vs insulin glargine and lixisenatide monocomponents
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1798, doi. 10.1111/dom.12980
- By:
- Publication type:
- Article
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 10, p. 1408, doi. 10.1111/dom.12961
- By:
- Publication type:
- Article
Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 205, doi. 10.1007/s13300-021-01180-1
- By:
- Publication type:
- Article
Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 12, p. 3231, doi. 10.1007/s13300-021-01156-1
- By:
- Publication type:
- Article
iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 1, p. 373, doi. 10.1007/s13300-017-0336-6
- By:
- Publication type:
- Article
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026-2035.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980
- Published in:
- 2017
- By:
- Publication type:
- journal article
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
- Published in:
- 2013
- By:
- Publication type:
- journal article
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine.
- Published in:
- Diabetes Care, 2013, v. 36, n. 9, p. 2497, doi. 10.2337/dc12-2462
- By:
- Publication type:
- Article
1-LB: Advancing Therapy in Basal Insulin Users with Type 2 Diabetes (T2D): Hypoglycemia as a Function of HbA1c in the SoliMix Trial.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-1-LB
- By:
- Publication type:
- Article
749-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-749-P
- By:
- Publication type:
- Article
748-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial in Participants in Europe.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-748-P
- By:
- Publication type:
- Article
746-P: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Nocturnal Hypoglycemia in the SoliMix Trial.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-746-P
- By:
- Publication type:
- Article
88-LB: Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-88-LB
- By:
- Publication type:
- Article
149-OR: LixiLan-G: A Randomized Trial Assessing Switching to iGlarLixi vs. Continuation of Daily or Weekly GLP-1RA in T2D Inadequately Controlled by a GLP-1RA and OAD(s).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-149-OR
- By:
- Publication type:
- Article
1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1146-P
- By:
- Publication type:
- Article
1139-P: Influence of Screening HbA<sub>1c</sub> Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1139-P
- By:
- Publication type:
- Article
1134-P: Efficacy of iGlarLixi in Adults with Type 2 Diabetes Inadequately Controlled on Two or More Oral Antidiabetic Agents.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1134-P
- By:
- Publication type:
- Article